BRAF and thyroid gland carcinoma: Following this, a clinically relevant antitumor activity of these BRAF inhibitors could also be demonstrated in patients with advanced V600E-mutant non–small-cell lung cancer, thyroid cancer, and hairy cell leukemia [19, 20].